AtriCure Receives CE-Mark for the EnCompass® Clamp

ATRC 10.01.2024

Full Press ReleaseSEC FilingsOur ATRC Tweets

About Gravity Analytica

Recent News

  • 02.12.2025 - Q4 2024 AtriCure, Inc. Earnings Conference Call
  • 01.22.2025 - AtriCure to Announce Fourth Quarter and Full Year 2024 Financial Results
  • 01.15.2025 - 43rd Annual J.P. Morgan Healthcare Conference

Recent Filings

  • 01.13.2025 - EX-99.1 EX-99.1
  • 01.13.2025 - 8-K Current report
  • 12.12.2024 - 4 Statement of changes in beneficial ownership of securities
PDF Version

Approval provides new catalyst for AtriCure’s international growth

MASON, Ohio--(BUSINESS WIRE)--Oct. 1, 2024--AtriCure, Inc.(Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it has received regulatory approval to sell the EnCompass® Clamp in CE-marked countries in theEuropean Union, and European surgeons have recently performed the first series of cases with AtriCure’s EnCompass Clamp. The EnCompass Clamp received FDA 510(K) clearance and was launched inthe United Statesin 2022.

“Launching our EnCompass Clamp inEuroperepresents a significant expansion of our product line internationally,” saidMichael Carrel, President and CEO ofAtriCure. “We have seen this product have a positive impact inthe United Statesover the last two years by advancing treatment concomitant to cardiac surgery. We are excited to offer this safe, innovative, and effective therapy to patients and our physician partners in Europe.”

The EnCompass Clamp provides a simpler and faster approach to ablating the heart in open-chest procedures, allowing physicians to perform a comprehensive epicardial ablation of the left atrium in just a few minutes. The EnCompass Clamp includes the features of AtriCure’s existing SynergyTM Clamp family, such as parallel closure, uniform pressure, and custom power using Synergy radiofrequency (RF). The EnCompass Clamp also allows for easier placement using a magnetic guide, which enables more efficient procedures by minimizing tissue dissection. Further, the EnCompass Clamp is designed to fit cardiac anatomy, supporting surgical ablation in procedures where the atrium would normally not be opened such as CABG and AVR.AtriCureestimates approximately 400,000 cardiac surgeries occur annually in theEuropean Union.

Forward-Looking Statements

This press release contains “forward-looking statements”– that is, statements related to future events that by their nature address matters that are uncertain. Actual results could differ materially. For details on the uncertainties that may cause our actual results to be materially different than those expressed in our forward-looking statements, visithttp://www.atricure.com/forward-looking-statementsas well as our Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q which contain risk factors. We assume no obligation to update any forward-looking statements contained in this release and the related attachment as a result of new information or future events or developments, except as may be required by law.

AboutAtriCure

AtriCure, Inc.provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 37 million people worldwide. Electrophysiologists, cardiothoracic and thoracic surgeons around the globe useAtriCuretechnologies for the treatment of Afib, reduction of Afib related complications and post-operative pain management. AtriCure’s Isolator® SynergyTM Ablation System is the first medical device to receive FDA approval for the treatment of persistent Afib. AtriCure’s AtriClip® Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide. AtriCure’s Hybrid AFTM Therapy is a minimally invasive procedure that provides a lasting solution for long-standing persistent Afib patients. AtriCure’s cryoICE cryoSPHERE® probes are cleared for temporary ablation of peripheral nerves to block pain, providing pain relief in cardiac and thoracic procedures. For more information, visitAtriCure.comor follow us on X (formerly Twitter) @AtriCure.

View source version onbusinesswire.com:https://www.businesswire.com/news/home/20241001409853/en/

Angie WirickInvestor RelationsChief Financial Officer(513) 755-5334awirick@atricure.com

Valerie Storch-WillhausMedia RelationsVice President,Corporate Marketing & Communications(612) 605-3311vstorch-willhaus@atricure.com

Source:AtriCure, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com